1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Pipeline Review: Large Potential Overactive Bladder Population Beckons

 
• By Emily Hayes

Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.

Human Body Organs (Urinary Bladder). 3D

The late-stage pipeline for the common condition of overactive bladder may be sparse, but the early-to-mid stage pipeline holds potential for new treatment options in the future – and the population is growing.

Overactive bladder refers to the frequent need to urinate – more than eight times per day or more than once...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

AbbVie Makes Big Autoimmune CAR-T Play With Capstan Acquisition

 
• By Alaric DeArment

The drugmaker will spend up to $2.1bn to acquire the privately held biotech firm and its targeted lipid nanoparticle technology platform, with an anti-CD19 asset in the clinic.

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.